강재헌 교수 연구실
article|
gold
·인용수 1
·2025
OP01-5 Efficacy and safety of larotrectinib in NTRK fusion-positive solid tumor patients: A multi-center retrospective study
Shirley Lee, Soo Jin Park, Kichul Shin, Hyun Ae Jung, Sejung Park, Yong Jae Lee, Wonyoung Choi, Hong‐Sik Kim, Chang-Geun Kim, H.R. Kim, Sang Byung Bae, K.E. Lee, Kyung-Woo Lee, E.J. Kang, So Jeong Yoon, Dong‐Jun Lim, Jae‐Heon Kang
ESMO Open
초록
Background: The neurotrophic tyrosine receptor kinase (NTRK) fusion is an oncogenic driver found in various solid tumors.Larotrectinib is a highly selective TRK inhibitor and was approved for the treatment of advanced NTRK fusion-positive solid tumors by MFDS in 2020.However, the pivotal clinical trial includes only selected and fit patients with small proportion (less than 5%) of Asian ethnicity.
키워드
Center (category theory)Retrospective cohort studyFusionMedicineOncologyBusinessInternal medicineChemistryCrystallographyPhilosophy